By Fineline Cube 
Zhaoke Ophthalmology (HKG: 6622) announced expanded distribution agreements for BRIMOCHOL PF to include Singapore and Vietnam, adding AFT Pharmaceuticals and Senju Pharmaceutical as its seventh and eighth commercialization partners for the presbyopia treatment.
Partnership Structure & Market Expansion
| Item | Detail |
|---|---|
| Company | Zhaoke Ophthalmology (6622.HK) |
| Product | BRIMOCHOL PF (preservative‑free, once‑daily pupil‑modulating eye drops) |
| Indication | Correction of near vision loss caused by presbyopia |
| Partner 1 | AFT Pharmaceuticals Limited (Australia) – exclusive rights for Singapore |
| Partner 2 | Senju Pharmaceutical Co., Ltd. (Japan) – exclusive rights for Vietnam |
| Rights Granted | Regulatory filing, importation, promotion, distribution, and sale |
| Co‑developer | Tenpoint Therapeutics Ltd |
| Strategic Significance | 7th and 8th commercialization partnerships, demonstrating robust global expansion |
Product Innovation & Clinical Profile
- First‑in‑Class: BRIMOCHOL PF is a preservative‑free, once‑daily formulation that modulates pupil size to restore near vision in presbyopic patients
- Mechanism: Pilocarpine‑based pupil modulation improves depth of focus without affecting distance vision
- Market Need: Presbyopia affects over 1.8 billion people globally, with Asia‑Pacific representing the fastest‑growing segment due to aging demographics
Market Impact & Commercial Outlook
- Southeast Asia Opportunity: Singapore and Vietnam combined represent $80–120 million addressable market for presbyopia therapies by 2030
- Competitive Advantage: BRIMOCHOL PF’s once‑daily, preservative‑free profile offers differentiation vs. multi‑dose preserved competitors
- Strategic Validation: Multi‑partner strategy reduces regional execution risk and accelerates market penetration across diverse regulatory environments
- Revenue Potential: Analysts estimate each new partnership could contribute $15–25 million in peak annual sales, with tiered royalties to Zhaoke Ophthalmology
- Next Steps: Regulatory submissions in Singapore and Vietnam expected Q2 2026, with commercial launches targeted for 2027
Forward‑Looking Statements
This brief contains forward‑looking statements regarding partnership contributions, regulatory timelines, and revenue projections for BRIMOCHOL PF. Actual results may differ due to regulatory review outcomes, competitive pressures, and market adoption rates.-Fineline Info & Tech